Organization Overview
Alternative names
ammonia n-13 (2021)
fludeoxyglucose f-18 (2015)
acetylsalicylic acid (aspirin) (1 trial)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin) (3 trials)
adenoviral vector expressing hsv-tk (4 trials)
aldesleukin (Proleukin) (4 trials)
alemtuzumab (campath) (14 trials)
allogeneic adipose derived mesenchymal stem cell (1 trial)
anti cd45 monoclonal antibody (7 trials)
autologous cd34+ cells (1 trial)
autologous cd34+ cells transduced withpsrs11.efs.il2rg.pre (3 trials)
autologous cmv-specific ctl (1 trial)
autologous mesenchymal stem cells (1 trial)
bevacizumab (avastin) (1 trial)
bicalutamide (casodex) (2 trials)
bone marrow derived mesenchymal stem cells (2 trials)
bortezomib (velcade) (1 trial)
capecitabine (xeloda) (1 trial)
carboplatin (paraplatin) (1 trial)
cyclophosphamide (cytoxan) (18 trials)
cyclosporine (sandimmune) (1 trial)
cytarabine (cytosar-u) (3 trials)
docetaxel (taxotere) (8 trials)
doxorubicin (Doxil) (2 trials)
durvalumab (imfinzi) (1 trial)
epirubicin (ellence) (1 trial)
everolimus (zortress) (3 trials)
Filgrastim (neupogen) (2 trials)
fludarabine (fludara) (19 trials)
fluorodopa (fluorodopa F18) (2 trials)
fluorouracil (efudex) (1 trial)
Ga 68 PSMA-11 (Illuccix) (1 trial)
gentamicin (garamycin) (1 trial)
hemopoietic stem cell (1 trial)
ixabepilone (ixempra) (3 trials)
ketoconazole (nizoral) (1 trial)
leuprolide (lupron) (2 trials)
mitoxantrone (novantrone) (1 trial)
modified vaccinia ankara-5t4 vaccine (3 trials)
multi-virus-specific cytotoxic t lymphocytes (1 trial)
ocrelizumab (ocrevus) (1 trial)
oxaliplatin (eloxatin) (1 trial)
phenytoin (mesantoin) (1 trial)
sargramostim (leukine) (6 trials)
sorafenib (nexavar) (2 trials)
tamoxifen (nolvadex) (1 trial)
temozolomide (temodar) (2 trials)
thalidomide (Thalomid) (1 trial)
topotecan (hycamtin) (2 trials)
trastuzumab (herceptin) (2 trials)
trastuzumab emtansine (kadcyla) (3 trials)
trivirus specific ctls for ebv, cmv and adenovirus infection (1 trial)
tumor associated antigen specific cytotoxic t lymphocytes (4 trials)
valaciclovir (Valtrex) (4 trials)
acetaminophen (tylenol) (1 trial)
adenovirus-specific t-cells (1 trial)
allodepleted t cells (1 trial)
allogeneic neuroblastoma cells (1 trial)
amlodipine (norvasc) (1 trial)
atezolizumab (Tecentriq) (1 trial)
autologous car.cd30 ebv specific-ctls (1 trial)
autologous ebv specific cytotoxic t lymphocytes (7 trials)
autologous regulatory t cells (1 trial)
autologous umbilical cord blood (1 trial)
azacitidine (vidaza) (1 trial)
barf1-specific cytotoxic t-lymphocytes (1 trial)
brentuximab vedotin (adcetris) (1 trial)
cd40 ligand and il-2-expressing tumor cells vaccine (1 trial)
cd40 ligand and il-2 gene modified autologous skin fibroblasts and tumor cells (1 trial)
cd40 ligand-expressing tumor cells (1 trial)
cd5.car/28zeta car t cells (1 trial)
cd7.car/28zeta car t cell (1 trial)
cmv/adv specific t cells (1 trial)
cmv-specific t-cells (1 trial)
COVID-19 convalescent plasma (1 trial)
denileukin diftitox (ontak) (1 trial)
dnr.npc-specific t cells (1 trial)
genetically modified ctls (1 trial)
her-2 pulsed dendritic cells (1 trial)
her2-specific t cells (1 trial)
her.car cmv-specific ctls (1 trial)
hpv specific t cells (1 trial)
icaspase9-transduced t cells (1 trial)
il-2 and human cd40 ligand plasmid gene modified autologous tumor cells (1 trial)
il-2 secreting and hcl4ol-expressing autologous b-cll cells (1 trial)
il-2-secreting cd40l-expressing autologous b-cll cells (1 trial)
indocyanine green (ic-green) (1 trial)
lenalidomide (revlimid) (1 trial)
methadone (methadose) (1 trial)
multivirus specific t cells (2 trials)
ny-eso-1, magea4, prame, survivin and ssx - specific t cells (1 trial)
oxycodone (oxycontin) (1 trial)
partially hla-matched virus specific t cells (1 trial)
peripheral blood lymphocytes (1 trial)
prame/ssx/mage-specific t cells (1 trial)
tgfbeta resistant her2/ebv-ctls (1 trial)
tgfbeta resistant lmp-specific ctls (1 trial)
varicella zoster virus glycoprotein e antigen (Shingrix) (1 trial)
gadopenteate dimeglumine (magnevist) (1 trial)
gadoteric acid (Dotarem) (1 trial)
Acute Lung Injury (Phase 1)
Acute Pain (Phase 4)
Adenocarcinoma (Phase 1)
Adenoviridae Infections (Phase 2)
Adrenal Insufficiency (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 2)
Anemia (Phase 2)
Anemia, Aplastic (Phase 2)
Anemia, Sickle Cell (Phase 2)
Aneurysm (Phase 4)
Anus Neoplasms (Phase 1)
Aortic Aneurysm (Phase 4)
Aortic Diseases (Phase 4)
Astrocytoma (Phase 2)
Atrial Fibrillation (Phase 3)
Autoimmune Diseases (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 1)
Cardiomyopathies (Phase 2)
Cardiomyopathy, Dilated (Phase 2)
Cholecystolithiasis (Phase 4)
Cholelithiasis (Phase 4)
Communicable Diseases (Phase 4)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
Coronavirus Infections (Phase 1)
Cytomegalovirus Infections (Phase 1)
Deafness (Phase 1)
Disease (Phase 2)
DNA Repair-Deficiency Disorders (Phase 1)
Emergencies (Phase 4)
Epstein-Barr Virus Infections (Phase 2)
Fanconi Anemia (Phase 2)
Fanconi Syndrome (Phase 2)
Gallstones (Phase 4)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hearing Loss (Phase 1)
Heart Failure (Phase 2)
Hematologic Diseases (Phase 2)
Hemoglobinopathies (Phase 2)
Hepatoblastoma (Phase 1)
Histiocytosis (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Hypotension (Phase 4)
Hypotension, Orthostatic (Phase 4)
Infections (Phase 4)
Intervertebral Disc Degeneration (Phase 1)
Intestinal Obstruction (Phase 4)
Irritable Bowel Syndrome (Phase 2)
Joint Diseases (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 4)
Leiomyosarcoma (Phase 1)
Leukemia (Phase 2)
Leukemia, B-Cell (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Liver Neoplasms (Phase 1)
Lung Diseases (Phase 1)
Lung Neoplasms (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoproliferative Disorders (Phase 2)
Melanoma (Phase 2)
Mental Disorders (Phase 2)
Metabolic Diseases (Phase 2)
Motor Neuron Disease (Phase 2)
Multiple Myeloma (Phase 2)
Multiple Sclerosis (Phase 2)
Muscular Dystrophies (Phase 3)
Muscular Dystrophy, Duchenne (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Myocardial Ischemia (Phase 4)
Nasopharyngeal Carcinoma (Phase 2)
Nasopharyngeal Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Site (Phase 1)
Neoplasms, Plasma Cell (Phase 2)
Neoplasms, Second Primary (Phase 2)
Neuroblastoma (Phase 1)
Osteosarcoma (Phase 1)
Pancreatic Neoplasms (Phase 2)
Paraproteinemias (Phase 2)
Parkinson Disease (Phase 4)
Preleukemia (Phase 2)
Prostatic Neoplasms (Phase 2)
Psychomotor Agitation (Phase 2)
Psychotic Disorders (Phase 2)
Rectal Neoplasms (Phase 2)
Recurrence (Phase 2)
Renal Insufficiency (Phase 2)
Respiratory Distress Syndrome (Phase 1)
Respiratory Distress Syndrome, Newborn (Phase 1)
Respiratory Insufficiency (Phase 1)
Restless Legs Syndrome (Phase 2)
Rhabdomyosarcoma (Phase 1)
Salivary Gland Neoplasms (Phase 1)
Sarcoma (Phase 1)
Schizophrenia (Phase 2)
Scleroderma, Diffuse (Phase 1)
Scleroderma, Systemic (Phase 1)
Sclerosis (Phase 2)
Shock (Phase 4)
Shock, Septic (Phase 4)
Skin Neoplasms (Phase 1)
Sleepiness (Phase 2)
Smooth Muscle Tumor (Phase 1)
Spondylolisthesis (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Suicide (Phase 1)
Syndrome (Phase 2)
Tachycardia (Phase 3)
Tachycardia, Ventricular (Phase 3)
Thalassemia (Phase 2)
Thoracic Neoplasms (Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 1)
Uveal Neoplasms (Phase 2)
Virus Diseases (Phase 4)
Vulvar Neoplasms (Phase 1)
